AI-driven opportunistic screening to improve population bone health.
Rho utilizes routinely captured x-rays to opportunistically identify patients at risk of osteoporosis.
‍
Licensed by Health Canada
FDA De Novo Marketing Authorization
This product is protected by U.S. Patent No. US11737704B2. All rights reserved.